ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Educational Symposium

Indications and Goals of Treatment in IgA Nephropathy and Focal Segmental Glomerulosclerosis

November 07, 2019 | 12:45 PM - 01:45 PM

Location: Liberty Ballroom, Marriott Marquis

Session Description

IgAN and FSGS are the two most common forms of glomerular disease worldwide. Neither disease has well-established effective treatments or drugs that are specifically licensed or approved by regulatory agencies. A key challenge in evaluating treatments for IgAN or FSGS is the usually relatively slow rate of progression of these kidney diseases toward ESKD or substantial loss of kidney function (e.g., 50% reduction in GFR). Drug development research for these diseases has been impeded by the heterogeneity of the patient populations with each disease diagnosis, as well as uncertainty about what measure of response to therapy robustly predicts long-term benefit in preserving kidney function.

Although controversies still persist, recent studies have addressed these important issues, notably in assessing the value of proteinuria reduction in IgAN and FSGS as a predictor of long-term kidney survival.

In this symposium, experts in the field of IgAN and FSGS update attendees on prognostic markers of disease progression, identifying patients at high risk of progression, and measures of response to treatment and their potential use in defining goals of treatment.

Support is provided by an educational grant from Retrophin, Inc.

Learning Objective(s)

  • Assess risk of progression in patients with FSGS or IgAN
  • Define measures of response to treatment and remission of disease that best predict renal survival in IgAN and FSGS

Learning Pathway(s)

  • Glomerular Diseases


  • Barbara S. Gillespie, MD, FASN


  • Introduction
    12:45 PM - 12:55 PM
    Barbara S. Gillespie, MD, FASN
  • Indications and Goals of Treatment in IgA Nephropathy
    12:55 PM - 01:15 PM
    Jürgen Floege, MD 
  • Indications and Goals of Treatment in FSGS
    01:15 PM - 01:35 PM
    Laura H. Mariani, MD, MS 
  • Questions and Answers
    01:35 PM - 01:45 PM